生物
肝细胞癌
CD8型
细胞毒性T细胞
转录组
癌症研究
免疫系统
先天免疫系统
免疫疗法
免疫学
肿瘤微环境
基因
基因表达
生物化学
体外
作者
Yun‐Fan Sun,Liang Wu,Yu Zhong,Kaiqian Zhou,Yong Hou,Zifei Wang,Zefan Zhang,Jiarui Xie,Chunqing Wang,Dandan Chen,Yaling Huang,Xiaochan Wei,Ying–Hong Shi,Zhikun Zhao,LI Yue-hua,Ziwei Guo,Qichao Yu,Liqin Xu,Giacomo Volpe,Shuang‐Jian Qiu
出处
期刊:Cell
[Cell Press]
日期:2020-12-23
卷期号:184 (2): 404-421.e16
被引量:599
标识
DOI:10.1016/j.cell.2020.11.041
摘要
Hepatocellular carcinoma (HCC) has high relapse and low 5-year survival rates. Single-cell profiling in relapsed HCC may aid in the design of effective anticancer therapies, including immunotherapies. We profiled the transcriptomes of ∼17,000 cells from 18 primary or early-relapse HCC cases. Early-relapse tumors have reduced levels of regulatory T cells, increased dendritic cells (DCs), and increased infiltrated CD8+ T cells, compared with primary tumors, in two independent cohorts. Remarkably, CD8+ T cells in recurrent tumors overexpressed KLRB1 (CD161) and displayed an innate-like low cytotoxic state, with low clonal expansion, unlike the classical exhausted state observed in primary HCC. The enrichment of these cells was associated with a worse prognosis. Differential gene expression and interaction analyses revealed potential immune evasion mechanisms in recurrent tumor cells that dampen DC antigen presentation and recruit innate-like CD8+ T cells. Our comprehensive picture of the HCC ecosystem provides deeper insights into immune evasion mechanisms associated with tumor relapse.
科研通智能强力驱动
Strongly Powered by AbleSci AI